person · Reporting owner

Ross Michael Jay

Disclosed activity across 7 companies

Tapewire entity: 126038
SEC CIK: 0001254452

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Astria Therapeutics, Inc.CATB · Entity 68888	Director	June 07, 2018	June 07, 2018
Deciphera Pharmaceuticals, Inc.DCPH · Entity 90033	Director	June 11, 2019	June 13, 2019
IVERIC bio, Inc.OPHT · Entity 111416	Director	May 23, 2018	July 11, 2018
SUTRO BIOPHARMA, INC.STRO · Entity 5797	Director · 10% owner	September 27, 2018	October 01, 2018
TRex Bio, Inc.TRXB · Entity 184308	Director	October 08, 2026	October 09, 2026
X4 Pharmaceuticals, IncASNS · Entity 5638	Director	June 05, 2018	June 07, 2018
Xilio Therapeutics, Inc.XLO · Entity 7122	Director	June 15, 2022	June 17, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Astria Therapeutics, Inc.

Report date June 07, 2018 · Filed June 07, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.48 · Expires 2028-06-06	Direct	14,000	Reported balance After 2018-06-07 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-06-07 · Grant · Acquired 14,000 · Balance 14,000 F1: This option was granted on June 7, 2018 and is scheduled to vest in full on June 7, 2019.

Filing footnotes · ownership attribution and instrument terms

F1: This option was granted on June 7, 2018 and is scheduled to vest in full on June 7, 2019.

Deciphera Pharmaceuticals, Inc.

Report date June 11, 2019 · Filed June 13, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.05 · Expires 2029-06-11	Direct	12,000	Reported balance After 2019-06-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-06-11 · Grant · Acquired 12,000 · Balance 12,000 F1: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in full on June 11, 2020, subject to continued service through such date.

Filing footnotes · ownership attribution and instrument terms

F1: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in full on June 11, 2020, subject to continued service through such date.

IVERIC bio, Inc.

Report date May 23, 2018 · Filed July 11, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.78 · Expires 2028-05-22	Direct	16,000	Reported balance After 2018-05-23 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-05-23 · Grant · Acquired 16,000 · Balance 16,000 F1: Subject to Reporting Person providing continued services to the Issuer and other terms and conditions under the Issuer's 2013 Stock Incentive Plan, the option will vest and become exercisable in 12 consecutive, equal installments on each consecutive monthly anniversary of the date of grant, until fully vested and exercisable on the first anniversary of the date of grant. Any unvested shares subject to the option will be accelerated in full one business day prior to the Issuer's 2019 annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: Subject to Reporting Person providing continued services to the Issuer and other terms and conditions under the Issuer's 2013 Stock Incentive Plan, the option will vest and become exercisable in 12 consecutive, equal installments on each consecutive monthly anniversary of the date of grant, until fully vested and exercisable on the first anniversary of the date of grant. Any unvested shares subject to the option will be accelerated in full one business day prior to the Issuer's 2019 annual meeting of stockholders.

SUTRO BIOPHARMA, INC.

Report date September 27, 2018 · Filed October 01, 2018

Filing footnotes · ownership attribution and instrument terms

F1: Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its initial public offering ("IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date.

F2: These securities are held of record by each of International Life Sciences Fund III Co-Investment, L.P., International Life Sciences Fund III (LP1) L.P. and International Life Sciences Fund III Strategic Partners L.P., as applicable (together, the "ILSF Funds"). ILSF III, LLC ("ILSF LLC") is the general partner of International Life Sciences Fund III (GP), L.P., which is the general partner of each of the ILSF Funds. The reporting person, a member of the issuer's board of directors, is a member of ILSF LLC's investment committee, and may be deemed to share voting and investment power over the securities held by the ILSF Funds. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

F3: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.

F4: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.

F5: These securities are held of record by each of SV Life Sciences Fund V, L.P. and SV Life Sciences Fund V Strategic Partners, L.P., as applicable (together, the "SVLSF Funds"). SVLSF V, LLC ("SVLSF LLC") is the general partner of SV Life Sciences Fund V (GP), L.P., which is the general partner of each of the SVLSF Funds. The reporting person, a member of the issuer's board of directors, is a member of SVLSF LLC's investment committee, and may be deemed to share voting and investment power over the securities held by the SVLSF Funds. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

F6: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.

F7: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.

F8: The warrant is exercisable at any time at the holder's election on a one-for one basis and automatically terminates on the completion of the issuer's initial public offering if not earlier exercised.

F9: Each share of the issuer's Series C Preferred Stock will automatically convert into 0.0370 share of the issuer's Common Stock immediately upon the closing of the issuer's IPO and has no expiration date.

TRex Bio, Inc.

Report date October 08, 2026 · Filed October 09, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2036-10-08	Direct	17,500	Reported balance After 2026-10-08 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-10-08 · Grant · Acquired 17,500 · Balance 17,500 F1: The option vests in full on October 8, 2027, subject to the reporting person's continued service through such date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in full on October 8, 2027, subject to the reporting person's continued service through such date.

X4 Pharmaceuticals, Inc

Report date June 05, 2018 · Filed June 07, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.99 · Expires 2028-06-04	Direct	10,000	Reported balance After 2018-06-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-06-05 · Grant · Acquired 10,000 · Balance 10,000 F1: The option becomes exercisable as to 1/12th of the shares underlying the award on the one-month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option becomes exercisable as to 1/12th of the shares underlying the award on the one-month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date.

Xilio Therapeutics, Inc.

Report date June 15, 2022 · Filed June 17, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.28 · Expires 2032-06-14	Direct	13,200	Reported balance After 2022-06-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-06-15 · Grant · Acquired 13,200 · Balance 13,200 F1: The option award was granted on June 15, 2022 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 15, 2023 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service as a director of the Issuer through the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option award was granted on June 15, 2022 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 15, 2023 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service as a director of the Issuer through the vesting date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 20, 2017 Filed Nov 20, 2017 17:28 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	ConversionSeries C Convertible Preferred Stock · Derivative	224,665	$0.00	$0.00	Disclosure SEC source: 0000899243-17-026997 · doc4.xml · derivative · entry 21 Ross Michael Jay · CIK 0001254452 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 111,955 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F4 · derivative.exercise_date: The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F4 · derivative.expiration_date: The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F6 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. The reporting person, a member of the investment committee of SVLSF V, LLC, may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document
November 20, 2017 Filed Nov 20, 2017 17:28 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	ConversionSeries B Convertible Preferred Stock · Derivative	15,246	$0.00	$0.00	Disclosure SEC source: 0000899243-17-026997 · doc4.xml · derivative · entry 20 Ross Michael Jay · CIK 0001254452 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 6,806 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F3 · derivative.exercise_date: The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F3 · derivative.expiration_date: The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F7 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. The reporting person, a member of the investment committee of SVLSF V, LLC, may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document
November 20, 2017 Filed Nov 20, 2017 17:28 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	ConversionSeries B Convertible Preferred Stock · Derivative	721,402	$0.00	$0.00	Disclosure SEC source: 0000899243-17-026997 · doc4.xml · derivative · entry 19 Ross Michael Jay · CIK 0001254452 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 322,102 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F3 · derivative.exercise_date: The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F3 · derivative.expiration_date: The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F6 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. The reporting person, a member of the investment committee of SVLSF V, LLC, may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document
November 20, 2017 Filed Nov 20, 2017 17:28 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	ConversionSeries A-2 Convertible Preferred Stock · Derivative	14,587	$0.00	$0.00	Disclosure SEC source: 0000899243-17-026997 · doc4.xml · derivative · entry 18 Ross Michael Jay · CIK 0001254452 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 5,219 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F2 · derivative.exercise_date: The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F2 · derivative.expiration_date: The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F7 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. The reporting person, a member of the investment committee of SVLSF V, LLC, may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document
November 20, 2017 Filed Nov 20, 2017 17:28 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	ConversionSeries A-2 Convertible Preferred Stock · Derivative	690,259	$0.00	$0.00	Disclosure SEC source: 0000899243-17-026997 · doc4.xml · derivative · entry 17 Ross Michael Jay · CIK 0001254452 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 247,010 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F2 · derivative.exercise_date: The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F2 · derivative.expiration_date: The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F6 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. The reporting person, a member of the investment committee of SVLSF V, LLC, may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document
November 20, 2017 Filed Nov 20, 2017 17:28 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	ConversionSeries A-1 Convertible Preferred Stock · Derivative	1,380	$0.00	$0.00	Disclosure SEC source: 0000899243-17-026997 · doc4.xml · derivative · entry 16 Ross Michael Jay · CIK 0001254452 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 404 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F7 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. The reporting person, a member of the investment committee of SVLSF V, LLC, may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document
November 20, 2017 Filed Nov 20, 2017 17:28 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	ConversionSeries A-1 Convertible Preferred Stock · Derivative	65,287	$0.00	$0.00	Disclosure SEC source: 0000899243-17-026997 · doc4.xml · derivative · entry 15 Ross Michael Jay · CIK 0001254452 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 19,128 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F6 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. The reporting person, a member of the investment committee of SVLSF V, LLC, may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document
November 20, 2017 Filed Nov 20, 2017 17:28 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	PurchaseCommon Stock	16,552	$10.00	$165,520.00	Disclosure SEC source: 0000899243-17-026997 · doc4.xml · nonDerivative · entry 14 Ross Michael Jay · CIK 0001254452 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,868,961 F9 · ownership.nature: These shares are owned directly by SV Life Sciences Fund VI Strategic Partners, L.P. ("SVLS VI SPP"). SVLS VI GP is the general partner of SVLS VI SPP. The general partner of SVLS VI GP is SVLSF VI, LLC. The reporting person, a member of the investment committee of SVLSF VI, LLC, may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document
November 20, 2017 Filed Nov 20, 2017 17:28 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	PurchaseCommon Stock	483,448	$10.00	$4,834,480.00	Disclosure SEC source: 0000899243-17-026997 · doc4.xml · nonDerivative · entry 13 Ross Michael Jay · CIK 0001254452 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,852,409 F8 · ownership.nature: These shares are owned directly by SV Life Sciences Fund VI, L.P. ("SVLS VI LP"). SV Life Sciences Fund VI (GP), LP ("SVLS VI GP") is the general partner of SVLS VI LP. The general partner of SVLS VI GP is SVLSF VI, LLC. The reporting person, a member of the investment committee of SVLSF VI, LLC, may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document
November 20, 2017 Filed Nov 20, 2017 17:28 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	ConversionCommon Stock	14,789	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-026997 · doc4.xml · nonDerivative · entry 12 Ross Michael Jay · CIK 0001254452 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,368,961 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F9 · ownership.nature: These shares are owned directly by SV Life Sciences Fund VI Strategic Partners, L.P. ("SVLS VI SPP"). SVLS VI GP is the general partner of SVLS VI SPP. The general partner of SVLS VI GP is SVLSF VI, LLC. The reporting person, a member of the investment committee of SVLSF VI, LLC, may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document
November 20, 2017 Filed Nov 20, 2017 17:28 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	ConversionCommon Stock	431,980	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-026997 · doc4.xml · nonDerivative · entry 11 Ross Michael Jay · CIK 0001254452 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,354,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F8 · ownership.nature: These shares are owned directly by SV Life Sciences Fund VI, L.P. ("SVLS VI LP"). SV Life Sciences Fund VI (GP), LP ("SVLS VI GP") is the general partner of SVLS VI LP. The general partner of SVLS VI GP is SVLSF VI, LLC. The reporting person, a member of the investment committee of SVLSF VI, LLC, may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document
November 20, 2017 Filed Nov 20, 2017 17:28 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	ConversionCommon Stock	4,288	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-026997 · doc4.xml · nonDerivative · entry 10 Ross Michael Jay · CIK 0001254452 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 922,192 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F7 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. The reporting person, a member of the investment committee of SVLSF V, LLC, may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document
November 20, 2017 Filed Nov 20, 2017 17:28 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	ConversionCommon Stock	202,915	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-026997 · doc4.xml · nonDerivative · entry 9 Ross Michael Jay · CIK 0001254452 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 917,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F6 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. The reporting person, a member of the investment committee of SVLSF V, LLC, may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document
November 20, 2017 Filed Nov 20, 2017 17:28 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	ConversionCommon Stock	2,365	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-026997 · doc4.xml · nonDerivative · entry 8 Ross Michael Jay · CIK 0001254452 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 714,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F7 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. The reporting person, a member of the investment committee of SVLSF V, LLC, may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document
November 20, 2017 Filed Nov 20, 2017 17:28 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	ConversionCommon Stock	111,955	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-026997 · doc4.xml · nonDerivative · entry 7 Ross Michael Jay · CIK 0001254452 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 712,624 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F6 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. The reporting person, a member of the investment committee of SVLSF V, LLC, may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document
November 20, 2017 Filed Nov 20, 2017 17:28 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	ConversionCommon Stock	6,806	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-026997 · doc4.xml · nonDerivative · entry 6 Ross Michael Jay · CIK 0001254452 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 600,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F7 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. The reporting person, a member of the investment committee of SVLSF V, LLC, may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document
November 20, 2017 Filed Nov 20, 2017 17:28 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	ConversionCommon Stock	322,102	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-026997 · doc4.xml · nonDerivative · entry 5 Ross Michael Jay · CIK 0001254452 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 593,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F6 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. The reporting person, a member of the investment committee of SVLSF V, LLC, may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document
November 20, 2017 Filed Nov 20, 2017 17:28 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	ConversionCommon Stock	5,219	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-026997 · doc4.xml · nonDerivative · entry 4 Ross Michael Jay · CIK 0001254452 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 271,761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F7 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. The reporting person, a member of the investment committee of SVLSF V, LLC, may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document
November 20, 2017 Filed Nov 20, 2017 17:28 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	ConversionCommon Stock	247,010	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-026997 · doc4.xml · nonDerivative · entry 3 Ross Michael Jay · CIK 0001254452 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 266,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F6 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. The reporting person, a member of the investment committee of SVLSF V, LLC, may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document
November 20, 2017 Filed Nov 20, 2017 17:28 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	ConversionCommon Stock	404	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-026997 · doc4.xml · nonDerivative · entry 2 Ross Michael Jay · CIK 0001254452 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 19,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F7 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. The reporting person, a member of the investment committee of SVLSF V, LLC, may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document
November 20, 2017 Filed Nov 20, 2017 17:28 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	ConversionCommon Stock	19,128	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-026997 · doc4.xml · nonDerivative · entry 1 Ross Michael Jay · CIK 0001254452 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 19,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. F6 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. The reporting person, a member of the investment committee of SVLSF V, LLC, may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document
November 15, 2017 Filed Dec 1, 2017 17:19 UTC	X4 Pharmaceuticals, Inc ASNS · Entity 5638	GrantStock Option (right to buy) · Derivative	7,324	$0.00 Strike: $10.00	$0.00	Disclosure SEC source: 0000899243-17-027824 · doc4.xml · derivative · entry 1 Ross Michael Jay · CIK 0001254452 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,324 Underlying: Common Stock · 7,324 shares Expires 2027-11-14 F1 · security: Consists of an automatic stock option grant that was made on November 15, 2017, the date of the effectiveness of the registration statement for the issuer's initial public offering, under the issuer's director compensation program. F2 · derivative.exercise_date: The option becomes exercisable as to 33.3333% of the shares underlying the award on the first anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date. Read SEC document
November 15, 2017 Filed Mar 5, 2018 17:03 UTC Amendment	X4 Pharmaceuticals, Inc ASNS · Entity 5638	GrantCommon Stock (right to buy) · Derivative	25,000	$0.00 Strike: $10.00	$0.00	Disclosure SEC source: 0001209191-18-016597 · doc4a.xml · derivative · entry 1 Ross Michael Jay · CIK 0001254452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-11-14 F1 · shares: Consists of an automatic stock option grant that was made pursuant to the issuer's director compensation policy on November 15, 2017, the date of effectiveness of the registration statement for the issuer's initial public offering. Under the terms of the policy, the Reporting Person received an option to purchase 25,000 shares. Due to a clerical error, the original Form 4 filed on December 1, 2017 erroneously reported an option grant of 7,324 shares. This Amendment to Form 4 is filed solely to correct the share number. F2 · derivative.exercise_date: The option becomes exercisable as to 33.3333% of the shares underlying the award on the first anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date. Read SEC document
July 27, 2017 Filed Jul 28, 2017 16:02 UTC	Astria Therapeutics, Inc. CATB · Entity 68888	GrantStock Option (right to buy) · Derivative	6,500	$0.00 Strike: $1.27	$0.00	Disclosure SEC source: 0001179110-17-010768 · edgar.xml · derivative · entry 1 ROSS MICHAEL JAY · CIK 0001254452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2027-07-26 F1 · derivative.exercise_date: This option was granted on July 27, 2017 and is scheduled to vest in full on June 7, 2018. Read SEC document
May 19, 2017 Filed May 22, 2017 16:10 UTC	IVERIC bio, Inc. OPHT · Entity 111416	GrantStock Option (right to buy) · Derivative	16,000	$0.00 Strike: $2.46	$0.00	Disclosure SEC source: 0000899243-17-014034 · doc4.xml · derivative · entry 3 ROSS MICHAEL JAY · CIK 0001254452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2027-05-18 F3 · derivative.exercise_date: Subject to Reporting Person providing continued services to the Issuer and other terms and conditions under a stock option agreement by and between the Reporting Person and the Issuer, The option will vest and become exercisable in 12 consecutive, equal monthly installments commencing on June 19, 2017 until fully vested and exercisable on the first anniversary of the date of grant. Any unvested shares subject to the option will be accelerated in full one business day prior to the Issuer's 2018 annual meeting of stockholders. Read SEC document
May 18, 2017 Filed May 22, 2017 16:10 UTC	IVERIC bio, Inc. OPHT · Entity 111416	Exercise / conversionRestricted Stock Units · Derivative	1,750	$0.00	$0.00	Disclosure SEC source: 0000899243-17-014034 · doc4.xml · derivative · entry 2 ROSS MICHAEL JAY · CIK 0001254452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F2 · derivative.exercise_date: As previously reported, on June 2, 2016 the Issuer awarded the Reporting Person a Restricted Stock Unit award which represented the contingent right to receive 1,750 shares of Issuer common stock. Pursuant to the terms of a Restricted Stock Unit Agreement by and between the Reporting Person and the Issuer, this Restricted Stock Unit award vested on May 18, 2017 with respect to 100% of the shares subject to the award, and the shares were issued to the Reporting Person. F2 · derivative.expiration_date: As previously reported, on June 2, 2016 the Issuer awarded the Reporting Person a Restricted Stock Unit award which represented the contingent right to receive 1,750 shares of Issuer common stock. Pursuant to the terms of a Restricted Stock Unit Agreement by and between the Reporting Person and the Issuer, this Restricted Stock Unit award vested on May 18, 2017 with respect to 100% of the shares subject to the award, and the shares were issued to the Reporting Person. Read SEC document
May 18, 2017 Filed May 22, 2017 16:10 UTC	IVERIC bio, Inc. OPHT · Entity 111416	Exercise / conversionCommon Stock	1,750	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-014034 · doc4.xml · nonDerivative · entry 1 ROSS MICHAEL JAY · CIK 0001254452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.